Drug Approval | May 18, 2022
Themis Medicare gets add on approval for Viralex
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
The innovative Fixed-Dose Combination will help improving the glycemic control among adult patients with insulin resistance, those whose diabetes is uncontrolled by metformin; and also those who require addition of Teneliglitptin and Pioglitazone as separate drugs.
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections
Corbevax is administered through an intramuscular route with two doses scheduled 28 days apart and is stored between 2 degrees celsius to 8 degrees celsius
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
The drug is priced at Rs 2000 for a course of 40 tablets
It has also been granted permission to conduct trials for booster dose
Subscribe To Our Newsletter & Stay Updated
